These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 16267742)

  • 21. Relationship between human T lymphotropic virus (HTLV) type 1/2 viral burden and clinical and treatment parameters among patients with HIV type 1 and HTLV-1/2 coinfection.
    Beilke MA; Traina-Dorge VL; Sirois M; Bhuiyan A; Murphy EL; Walls JM; Fagan R; Winsor EL; Kissinger PJ
    Clin Infect Dis; 2007 May; 44(9):1229-34. PubMed ID: 17407044
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome.
    García-Gascó P; Maida I; Blanco F; Barreiro P; Martín-Carbonero L; Vispo E; González-Lahoz J; Soriano V
    J Antimicrob Chemother; 2008 Mar; 61(3):699-704. PubMed ID: 18192682
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Decreasing CD4+ T-cell count during suppressed or low-level viraemia in patients with HIV infection.
    Anderson AM; Kosinski AS; Bartlett JA
    Antivir Ther; 2007; 12(7):1041-8. PubMed ID: 18018762
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral lesions as clinical markers of highly active antiretroviral therapy failure: a nested case-control study in Mexico City.
    Ramírez-Amador V; Ponce-de-León S; Anaya-Saavedra G; Crabtree Ramírez B; Sierra-Madero J
    Clin Infect Dis; 2007 Oct; 45(7):925-32. PubMed ID: 17806063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial.
    Zuckerman RA; Lucchetti A; Whittington WL; Sanchez J; Coombs RW; Zuñiga R; Magaret AS; Wald A; Corey L; Celum C
    J Infect Dis; 2007 Nov; 196(10):1500-8. PubMed ID: 18008230
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Behavior of serum human major histocompatibility complex class I antigen levels in human immunodeficiency virus-infected patients during antiretroviral therapy: correlation with clinical outcome.
    Murdaca G; Contini P; Setti M; Cagnati P; Villa R; Lantieri F; Indiveri F; Puppo F
    Hum Immunol; 2007 Nov; 68(11):894-900. PubMed ID: 18082568
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation.
    Bonora S; Nicastri E; Calcagno A; Gonzalez de Requena D; D'Ettorre G; Sarmati L; Palmisano L; Vullo V; Di Perri G; Andreoni M
    J Med Virol; 2009 Mar; 81(3):400-5. PubMed ID: 19152404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Maintaining reduced viral fitness and CD4 response in HIV-infected patients with viremia receiving a boosted protease inhibitor.
    Grant P; Taylor J; Cain P; Short W; Gallant J; Farthing C; Thal G; Coakley E; Zolopa A
    Clin Infect Dis; 2009 Mar; 48(5):680-2. PubMed ID: 19191657
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART.
    Isgrò A; Leti W; De Santis W; Marziali M; Esposito A; Fimiani C; Luzi G; Pinti M; Cossarizza A; Aiuti F; Mezzaroma I
    Clin Infect Dis; 2008 Jun; 46(12):1902-10. PubMed ID: 18462177
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of GB virus C on response to antiretroviral therapy in HIV-infected Brazilians.
    Souza IE; Zhang W; Diaz RS; Chaloner K; Klinzman D; Stapleton JT
    HIV Med; 2006 Jan; 7(1):25-31. PubMed ID: 16313289
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus.
    Stephan C; Berger A; Carlebach A; Lutz T; Bickel M; Klauke S; Staszewski S; Stuermer M
    J Antimicrob Chemother; 2005 Dec; 56(6):1087-93. PubMed ID: 16269552
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relative sensitivities of licensed nucleic acid amplification tests for detection of viremia in early human immunodeficiency virus and hepatitis C virus infection.
    Busch MP; Glynn SA; Wright DJ; Hirschkorn D; Laycock ME; McAuley J; Tu Y; Giachetti C; Gallarda J; Heitman J; Kleinman SH;
    Transfusion; 2005 Dec; 45(12):1853-63. PubMed ID: 16371038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Surgical outcomes in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy.
    Horberg MA; Hurley LB; Klein DB; Follansbee SE; Quesenberry C; Flamm JA; Green GM; Luu T
    Arch Surg; 2006 Dec; 141(12):1238-45. PubMed ID: 17178967
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the Abbott Real-Time HIV-1 quantitative assay with dried blood spot specimens.
    Marconi A; Balestrieri M; Comastri G; Pulvirenti FR; Gennari W; Tagliazucchi S; Pecorari M; Borghi V; Marri D; Zazzi M
    Clin Microbiol Infect; 2009 Jan; 15(1):93-7. PubMed ID: 19220340
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy.
    Pessôa MG; Gazzard B; Huang AK; Brandão-Mello CE; Cassetti I; Mendes-Corrêa MC; Soriano V; Phiri P; Hall A; Brett-Smith H
    AIDS; 2008 Sep; 22(14):1779-87. PubMed ID: 18753861
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma.
    Marcelin AG; Tubiana R; Lambert-Niclot S; Lefebvre G; Dominguez S; Bonmarchand M; Vauthier-Brouzes D; Marguet F; Mousset-Simeon N; Peytavin G; Poirot C
    AIDS; 2008 Aug; 22(13):1677-9. PubMed ID: 18670231
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Persistent differences in the antiviral effects of highly active antiretroviral therapy in the blood and male genital tract.
    Pasquier CJ; Moinard N; Sauné K; Souyris C; Lavit M; Daudin M; Izopet J; Bujan L
    AIDS; 2008 Sep; 22(14):1894-6. PubMed ID: 18753873
    [No Abstract]   [Full Text] [Related]  

  • 39. Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma.
    Antinori A; Perno CF; Giancola ML; Forbici F; Ippolito G; Hoetelmans RM; Piscitelli SC
    Clin Infect Dis; 2005 Dec; 41(12):1787-93. PubMed ID: 16288405
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human immunodeficiency virus infection and levels of Dehydroepiandrosterone sulfate in plasma among Indians.
    Kandathil AJ; Kannangai R; David S; Selvakumar R; Job V; Abraham OC; Sridharan G
    Clin Diagn Lab Immunol; 2005 Sep; 12(9):1117-8. PubMed ID: 16148181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.